Chronic Myeloid Leukemia in Children: Immune Function and Vaccinations

Area of Science:

• Pediatric Hematology/Oncology
• Immunology
• Infectious Diseases

Background:

• Children with chronic myeloid leukemia (CML) require long-term tyrosine kinase inhibitor (TKI) treatment.
• Limited understanding of TKI-induced immune dysfunction impacts routine childhood immunizations.
• TKIs such as imatinib, dasatinib, and nilotinib are commonly used in pediatric CML.

Purpose of the Study:

• To review the impact of pediatric-approved TKIs on immune function in children with CML.
• To assess the implications of TKI therapy on the safety and efficacy of childhood immunizations.
• To discuss surveillance strategies and vaccination recommendations for this patient population.

Main Methods:

• Literature review of studies on TKI effects on pediatric immune function.
• Analysis of data regarding vaccine efficacy and safety in children with CML on TKI therapy.
• Discussion of specific vaccine types (inactivated and live-attenuated) and COVID-19 considerations.

Main Results:

• TKI treatment for CML can lead to mild humoral and cellular immune dysfunction.
• Inactivated vaccines (e.g., influenza, pneumococcal) are permissible during TKI therapy, though efficacy might be reduced.
• Live vaccines (e.g., varicella, MMR) may be administered cautiously under specific circumstances.

Conclusions:

• Infectious complications are infrequent in children with CML on TKI therapy.
• Routine immunizations are crucial for maintaining health in children with CML.
• Vaccination decisions for children with CML receiving TKI therapy require careful, individualized consideration.